A Phase II Study of BI-505 in Smoldering Multiple Myeloma

NCT01838369 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Smoldering Multiple Myeloma

Interventions

DRUG: BI-505

Sponsor

BioInvent International AB